Table 1.
Different compounds and their combinations in clinical trials. +/− indicates a study performed with or without a specified compound, mAb: monoclonal antibody, IgG: immunoglobulin G.
| Immune Checkpoint | Compound Name | Combination | Phase | Stage | ClinicalTrials.gov ID |
|---|---|---|---|---|---|
| LAG-3 |
IMP-321 LAG-3Ig fusion protein and APC activator |
Pembrolizumab | I | Unresectable or Metastatic Melanoma | NCT02676869 |
| Tumor Antigenic Peptides and Montanide | I/II | Stage II-IV Melanoma | NCT01308294 | ||
| Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 | I/II | Disease-Free Melanoma | NCT00365937 | ||
| Cyclophosphamide, fludarabine, Melan-A VLP vaccine |
I | Metastatic Melanoma | NCT00324623 | ||
| +/− Avelumab | I | Solid Tumors | NCT03252938 | ||
|
Relatlimab (BMS-986213) Fully human IgG4 mAb |
Nivolumab | I | Advanced Solid Tumors | NCT03335540 | |
| II | MSI-H Solid Tumors | NCT03607890 | |||
| Stage IIIB/IV Melanomas | NCT02519322 | ||||
| Locally Advanced, Unresectable, or Metastatic Melanoma | NCT03724968 | ||||
| II/III | Advanced Melanoma | NCT03470922 | |||
| +/− Nivolumab | I | Advanced Solid Tumors | NCT02966548 | ||
| I/II | Solid Tumors Including Melanoma | NCT01968109 | |||
| II | Metastatic Melanoma | NCT03743766 | |||
| Nivolumab + rHuPH20 | I | Cancer including Melanoma | NCT04112498 | ||
| Nivolumab + BMS-986205 + Ipilimumab | I/II | Solid Cancers | NCT03459222 | ||
| Ipilimumab | I | Advanced Melanoma | NCT03978611 | ||
|
Ieramilimab (LAG525) Fully human IgG4 mAb |
PDR001 | I/II | Advanced Solid Tumor Including Melanoma | NCT02460224 | |
| PDR001, capmatinib, canakinumab, ribociclib |
II | Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | ||
|
MK-4280 Fully human IgG4 mAb |
Pembrolizumab + Oxaliplatin+ Irinotecan + Leucovorin (Calcium Folinate) + Fluorouracil [5-FU] + MK-4280A | I | Advanced Solid Tumors | NCT02720068 | |
|
REGN3767 Fully human mAb |
+/− cemiplimab | I | Advanced Cancers | NCT03005782 | |
|
TSR-033 Fully human IgG4 mAb |
Anti-PD-1 | I | Advanced Solid Tumors | NCT03250832 | |
|
BI 754111 Humanized IgG4 mAb |
BI 754091(anti-pd1) | Early Phase I | Neoplasms | NCT03433898 | |
| II | Advanced Solid Tumors | NCT03697304 | |||
| +/− BI 754091(anti-pd1) | I | Advanced Cancers | NCT03156114 | ||
| BI 754091(anti-pd1) + BI907828 | I | Advanced Solid Tumors | NCT03964233 | ||
|
Sym022 Fully human Fc-inert mAb |
- | I | Advanced Solid Tumor | NCT03489369 | |
| Sym021 (PD1) | I | Advanced Solid Tumor | NCT03311412 | ||
|
FS118 Bispecific antibody binding both LAG-3 and PD-L1 |
- | I | Advanced and Metastatic Cancer | NCT03440437 | |
|
MGD013 Bispecific DART protein binding both LAG-3 and PD-1 |
+/− margetuximab (anti-HER2) | I | Advanced Solid Tumors | NCT03219268 | |
|
INCAGN02385 Fc engineered IgG1k antibody |
- | I | Advanced Malignancies | NCT03538028 | |
| TIM-3 |
TSR-022 Humanized mAb |
TSR-042, TSR-033 | I | Advanced Solid Tumors | NCT02817633 |
| Niraparib, TSR-042, Bevacizumab, Platinum-Based chemotherapy | I | Advanced Solid Tumors | NCT03307785 | ||
|
MBG453 Humanized IgG4 monoclonal antibody |
PDR001 | I/II | Advanced Malignancies. | NCT02608268 | |
|
Sym023 Fully human mAb |
- | I | Advanced Solid Tumor | NCT03489343 | |
| Sym021, Sym022 | I | Advanced Solid Tumor or Lymphomas | NCT03311412 | ||
|
INCAGN2390 mAb |
- | I | Advanced Malignancies | NCT03652077 | |
|
LY3321367 mAb |
LY3300054 | I | Advanced Solid Tumor | NCT03099109 | |
| LY3300054, Ramucirumab, Abemaciclib, Merestinib |
I | Advanced Solid Tumor | NCT02791334 | ||
|
BMS-986258 Fully human mAb |
Nivolumab, rHuPH20 | I/II | Advanced Solid Tumor | NCT03446040 | |
| SHR-1702 | Camrelizumab | I | Advanced Solid Tumor | NCT03871855 | |
|
RO7121661 Anti-PD-1/TIM3 bispecific Ab |
- | I | Advanced Solid Tumor | NCT03708328 | |
|
BGB-A425 Humanized, IgG1-variant monoclonal antibody |
Tislelizumab | I/II | Locally Advanced or Metastatic Solid Tumors | NCT03744468 | |
|
LY3415244 Anti PD-L1/TIM-3 Bispecific Antibody |
- | I | Advanced Solid Tumor | NCT03752177 | |
| TIGIT |
MK-7684 IgG1 mAb |
Pembrolizumab | I | Advanced Solid Tumor | NCT02964013 |
|
Etigilimab/OMP-313 M32 mAb |
Nivolumab | I | Advanced Solid Tumor | NCT03119428 | |
|
Tiragolumab/MTIG7192A/RG-6058 Fully human IgG1 mAb |
Atezolizumab | I | Advanced Solid Tumor | NCT02794571 | |
|
BMS-986207 IgG1 mAb (FcyR-null) |
Nivolumab | I/II | Advanced Solid Tumor | NCT02913313 | |
|
AB-154 Fully humanized IgG1 mAb |
AB122 | I | Advanced Malignancies | NCT03628677 | |
|
ASP-8374 IgG1 mAb (FcyR-null) |
Pembrolizumab | I | Advanced Solid Tumors | NCT03260322 | |
| - | I | Advanced Solid Tumor | NCT03945253 | ||
| VISTA |
JNJ-61610588 Complete human mAb |
- | I | Advanced Solid Tumor | NCT02671955 |
|
CA-170d Small orally available molecule that directly targets PD-L1/PD-L2, and VISTA |
- | I | Advanced Solid Tumors | NCT02812875 | |
| B7-H3 |
Enoblituzumab/MGA271 Humanized IgG1κ mAb |
- | I | Advanced Solid Tumors | NCT01391143 |
| Ipilimumab | I | Advanced Solid Tumors | NCT02381314 | ||
| Pembrolizumab | I | Advanced Solid Tumors | NCT02475213 | ||
| - | I | Children with B7-H3-Expressing Solid Tumors | NCT02982941 | ||
|
MGD009 Humanized, bispecific DART molecule that recognizes both B7-H3 and CD3 |
MGA012 | I | Advanced Solid Tumors | NCT03406949 | |
| - | I | B7-H3-Expressing Tumors | NCT02628535 |